| scholarly article | Q13442814 |
| P50 | author | Ömer H. Yilmaz | Q98513567 |
| P2093 | author name string | Roderick T Bronson | |
| Philip N Tsichlis | |||
| Anthony C Faber | |||
| Kenneth E Hung | |||
| Eric S Martin | |||
| Erin M Coffee | |||
| Jatin Roper | |||
| Jihye Yun | |||
| Larissa Georgeon-Richard | |||
| Lily Keung | |||
| Mark J Sinnamon | |||
| Peter Belmont | |||
| Wei Vivian Wang | |||
| P2860 | cites work | Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models | Q24306326 |
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
| The molecular rationale of Src inhibition in colorectal carcinomas | Q26853018 | ||
| Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor | Q27676347 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer | Q27851771 | ||
| Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma | Q44557425 | ||
| In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer | Q45842339 | ||
| Assessment of tumor development and wound healing using endoscopic techniques in mice. | Q50441228 | ||
| Prevalence of ras gene mutations in human colorectal cancers | Q59088716 | ||
| Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer | Q27852136 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing | Q28275103 | ||
| Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes | Q28307762 | ||
| The landscape of somatic copy-number alteration across human cancers | Q29547648 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 | Q29617043 | ||
| Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment | Q33667595 | ||
| The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer | Q34038031 | ||
| The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms | Q34165045 | ||
| RAS Interaction with PI3K: More Than Just Another Effector Pathway | Q34202692 | ||
| Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. | Q34248627 | ||
| PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 | ||
| PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling | Q35227481 | ||
| Delving deeper: MCL-1's contributions to normal and cancer biology | Q36494824 | ||
| Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma | Q36582547 | ||
| Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice | Q36869970 | ||
| Recurrent R-spondin fusions in colon cancer | Q36949683 | ||
| PUMA and BIM are required for oncogene inactivation-induced apoptosis. | Q37121933 | ||
| Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations | Q37269341 | ||
| TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma | Q37401151 | ||
| mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer | Q37605004 | ||
| Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. | Q37632641 | ||
| mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. | Q37680565 | ||
| Apoptosis in targeted therapy responses: the role of BIM. | Q38041733 | ||
| PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types | Q38084846 | ||
| Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations | Q38405477 | ||
| Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas | Q39384830 | ||
| TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. | Q39395631 | ||
| STK33 kinase activity is nonessential in KRAS-dependent cancer cells | Q39509593 | ||
| JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Δ716) mice. | Q39592405 | ||
| Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells | Q39843809 | ||
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 | ||
| Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy | Q40039847 | ||
| Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells | Q42437883 | ||
| Altered growth of human colon cancer cell lines disrupted at activated Ki-ras | Q42810367 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 204-211 | |
| P577 | publication date | 2014-02-24 | |
| P1433 | published in | Cancer Letters | Q326372 |
| P1476 | title | Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer | |
| P478 | volume | 347 |
| Q37301776 | Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer |
| Q89441275 | Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations |
| Q38868621 | Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. |
| Q55072491 | CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. |
| Q47558200 | Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. |
| Q26795724 | Colorectal cancer models for novel drug discovery |
| Q38757645 | Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes |
| Q36396095 | Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro |
| Q51068898 | Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. |
| Q26781362 | Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers |
| Q27324821 | Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer |
| Q48651245 | ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma |
| Q37421296 | Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. |
| Q38705367 | In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis |
| Q90221250 | Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth |
| Q94545577 | Integrating Genome-Wide Association Studies and Gene Expression Profiles With Chemical-Genes Interaction Networks to Identify Chemicals Associated With Colorectal Cancer |
| Q51819604 | Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer. |
| Q37705948 | LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer |
| Q38744494 | MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling |
| Q37252398 | PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma |
| Q47128334 | PKM2 is not required for colon cancer initiated by APC loss. |
| Q37301884 | Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging |
| Q58542302 | Targeting PP2A in cancer: Combination therapies |
| Q30239109 | Translating genomic profiling to gastrointestinal cancer treatment |
| Q37746259 | miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma |
Search more.